Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer

 
• By Sten Stovall

Phase III IMpassion130 study showed Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

Mammography test
Tecentriq posts positive results in triple negative breast cancer • Source: Shutterstock

More from Immuno-oncology

More from Anticancer